These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 1660089)

  • 1. [Antimycobacterial activities of a new quinolone, sparfloxacin].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro antimycobacterial activity of a new quinolone, NM394].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1993 Aug; 68(8):517-20. PubMed ID: 8397311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro antimycobacterial activity of a new quinolone, T-3761].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1995 Feb; 70(2):97-101. PubMed ID: 7699982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antimycobacterial activity of a newly synthesized fluoroquinolone, Y-26611].
    Tomioka H; Sato K; Saito H; Ikeda Y
    Kekkaku; 1992 Jul; 67(7):515-20. PubMed ID: 1331603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1993 Apr; 68(4):293-9. PubMed ID: 8497119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.
    Tomioka H; Saito H; Sato K
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1259-63. PubMed ID: 8392307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic potential of sparfloxacin for preventing mycobacterial infections].
    Kawahara S; Tada A; Takeuchi M; Kamisaka K; Okada C; Mishima Y; Soda R; Takahashi K; Kibata M; Nagare H
    Kekkaku; 1994 May; 69(5):351-6. PubMed ID: 8007520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
    Kawahara S; Tada A; Nagare H
    Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis].
    Kawahara S; Kamisaka K; Tada A; Nakada H; Mishima Y; Yoshimoto S; Matsuyama T; Kibata M; Nagare J
    Kekkaku; 1991 Jun; 66(6):429-31. PubMed ID: 1942726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antimicrobial activity of new quinolones against Mycobacterium avium and Mycobacterium intracellulare determined by the dilution methods using 7H11 agar and Ogawa egg media].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1993 May; 68(5):367-70. PubMed ID: 8331881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
    Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro antimycobacterial activities of a new quinolone, balofloxacin].
    Kawahara S; Tada A; Nagare H
    Kekkaku; 2001 Jan; 76(1):29-31. PubMed ID: 11211780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.
    Saito H; Tomioka H; Sato K; Dekio S
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2877-82. PubMed ID: 7695276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media].
    Yamane N; Chilima BZ; Tosaka M; Okazawa Y; Tanno K
    Kekkaku; 1996 Aug; 71(8):453-8. PubMed ID: 8831190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of a newly developed broth microdilution test method to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for mycobacteria].
    Yamane N; Nakasone I; Saitoh H; Kaneda M; Shimojima M; Yamashita K; Toyoda K; Okazawa Y
    Rinsho Byori; 1998 Jul; 46(7):719-27. PubMed ID: 9721542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections].
    Kawahara S; Nagare H
    Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy of pulmonary Mycobacterium kansasii infection].
    Mizutani S
    Kekkaku; 1996 Sep; 71(9):527-31. PubMed ID: 8914388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro activity of quinolones and macrolides against mycobacteria.
    Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
    J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
    Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T
    J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
    Tomioka H; Saito H
    Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.